Industry: Solutions for the anti-infective market
PhytoTEK is developing therapies to treat staphylococcal and streptococcal infections.
The company’s key technology is a unique extraction process for refining a plant extract known for its potent anti-staphylococcal and anti-streptococcal properties. Through multiple in vitro studies, PhytoTEK has demonstrated that its compound makes known lineages of Staphylococcus aureus and Streptococcus pneumoniae susceptible to antibiotics.
These infections currently pose a $3 billion total economic burden to the healthcare industry, with each staph-related infection about $15,000 to treat. Improved therapies for antibiotic-resistant infections are essential, and PhytoTEK’s solution could help meet this important need.